Literature DB >> 30414342

Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.

Leticia Muñoz1,2, María-José Borrero1,2, María Úbeda1,2, Elisa Conde3, Rosa Del Campo4, Macarena Rodríguez-Serrano3, Margaret Lario1,2, Ana-María Sánchez-Díaz4, Oscar Pastor5, David Díaz1,2,6, Laura García-Bermejo3, Jorge Monserrat1,2,6, Melchor Álvarez-Mon1,2,6, Agustín Albillos1,2,7.   

Abstract

In cirrhosis, intestinal dysbiosis, intestinal barrier impairment, and systemic immune system abnormalities lead to gut bacterial translocation (GBT) and bacterial infection. However, intestinal immune system dysfunction and its contribution to barrier damage are poorly understood. This study correlates immune system dysregulation in the intestines of rats at different stages of CCl4 -induced cirrhosis with barrier function and pathogenic microbiota. The following variables were addressed in the small intestine: intraepithelial lymphocyte (IEL) and lamina propria lymphocyte (LPL) activation status and cytokine production (flow cytometry), cytokine mRNA and protein expression (quantitative real-time PCR and immunofluorescence), microbiota composition of ileum content (16S recombinant DNA massive sequencing), permeability (fecal albumin loss), and epithelial junctions (immunohistochemistry and immunofluorescence). The intestinal mucosa in rats with cirrhosis showed a proinflammatory pattern of immune dysregulation in IELs and LPLs, which featured the expansion of activated lymphocytes, switch to a T helper 1 (Th1) regulatory pattern, and Th17 reduction. In rats with cirrhosis with ascites, this state was associated with epithelial junction protein disruption, fecal albumin loss, and GBT. Direct correlations (P < 0.01) were observed between elevated interferon gamma (IFNγ)-expressing T cytotoxic LPLs and fecal albumin and between inflammatory taxa abundance and IFNγ-producing immune cells in the ileum. Bowel decontamination led to redistributed microbiota composition, reduced proinflammatory activation of mucosal immune cells, normalized fecal albumin levels, and diminished GBT; but there were no modifications in Th17 depletion.
Conclusion: The intestinal mucosa of rats with cirrhosis acquires a proinflammatory profile of immune dysregulation that parallels the severity of cirrhosis; this impaired intestinal immune response is driven by gut dysbiosis and leads to disrupted barrier function, promoting GBT.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 30414342     DOI: 10.1002/hep.30349

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.

Authors:  Jasmohan S Bajaj; Nita H Salzman; Chathur Acharya; Richard K Sterling; Melanie B White; Edith A Gavis; Andrew Fagan; Michael Hayward; Mary L Holtz; Scott Matherly; Hannah Lee; Majdi Osman; Mohammad S Siddiqui; Michael Fuchs; Puneet Puri; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatology       Date:  2019-06-18       Impact factor: 17.425

Review 2.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

Review 3.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

Review 4.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

Review 5.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

6.  Mucosal immunity-mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer's patches.

Authors:  Sisi Lin; Subhajit Mukherjee; Juanjuan Li; Weiliang Hou; Chao Pan; Jinyao Liu
Journal:  Sci Adv       Date:  2021-05-12       Impact factor: 14.136

Review 7.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 8.  The Role of the Microbiome in Liver Cancer.

Authors:  Mar Moreno-Gonzalez; Naiara Beraza
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

9.  Antimicrobial Peptides Human Beta-Defensin-2 and -3 Protect the Gut During Candida albicans Infections Enhancing the Intestinal Barrier Integrity: In Vitro Study.

Authors:  Alessandra Fusco; Vittoria Savio; Maria Donniacuo; Brunella Perfetto; Giovanna Donnarumma
Journal:  Front Cell Infect Microbiol       Date:  2021-06-10       Impact factor: 5.293

10.  Effects of the Cistanche tubulosa Aqueous Extract on the Gut Microbiota of Mice with Intestinal Disorders.

Authors:  Xiaowei Bao; Dongwen Bai; Xiaolu Liu; Ying Wang; Lanjun Zeng; Chenye Wei; Weiquan Jin
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.